Objective.-The goal of this analysis was to provide a contemporary estimate of the burden of migraine, incorporating both direct and indirect costs, by comparing the costs of migraine patients to a matched group of patients without migraine in a large, nationally representative sample of commercially insured patients in the United States.
INTRODUCTION
Migraine is a complex neurological disease, characterized by recurrent, unilateral, pulsating headaches that last for 4 to 72 hours and are aggravated by routine physical activity. 1, 2 It is often accompanied by an array of symptoms that include nausea and/or vomiting, photophobia and phonophobia and, based on the frequency of headache, it is primarily classified into chronic and episodic migraine. 1 Migraine is the third most prevalent illness and is the sixth leading cause of years lived with disability (YLDs) in the world; in the United States, 14.2% of adults overall and approximately 19% of individuals in their peak employment years (ages 18-54) reported experiencing migraine or severe headache in the previous 3 months. [2] [3] [4] [5] Despite the availability of multiple acute and preventive pharmacological treatment options and a relatively stable migraine prevalence in the United States, 4 there has been a documented increase in migraine-related healthcare resource and pharmacy use. 6, 7 The economic burden of migraine in the United States is substantial for payers, patients, and employers. The annual cost associated with migraine, which included the cost of healthcare resources and lost productivity, was estimated at $36 billion in 2016. 2 Individuals with migraine have higher direct healthcare costs than those without migraine, 6, [8] [9] [10] [11] [12] and patients suffering from chronic migraine incur higher healthcare costs than do those with episodic migraine. 7, [13] [14] [15] [16] The direct cost burden of migraine includes the cost of acute migraine-specific treatments as well as the cost of conditions that are frequently comorbid with migraine, most notably, psychiatric conditions such as anxiety, and depression. 6, 12 The high prevalence of migraine during peak employment years has led to multiple studies on the impact of migraine on human productivity and the associated costs of productivity losses, often referred to as indirect costs. 7, 8, 11, 15, [17] [18] [19] [20] [21] The general approach to estimating indirect costs is to measure the number of days or hours of reduced productivity and then to monetize the time lost by applying an appropriate wage rate. Some studies estimated the indirect costs of migraine specifically to employers due to days missed from work; these studies typically measured days lost due to migraine using administrative records of workplace absence, shortterm (ST) or long-term (LT) disability, and/or workers' compensation. 11, 19 Other studies estimated the indirect costs of migraine using surveys to measure the number of self-reported days either missed or during which productivity was reduced due to migraine at work, school, or while performing household duties. 7, 8, 15, 20, 21 Due to the varying methodologies used to capture productivity loss (eg, administrative records vs self-report), the different components of productivity loss captured (eg, absenteeism vs presenteeism, paid vs unpaid work), and different wage rates used to monetize lost productive time, estimates of the indirect costs of migraine and their relative contribution to the total cost burden of migraine vary widely. As described, numerous studies have shown that migraine is associated with increased direct and indirect costs. Use of migraine prophylaxis has been shown to decrease the utilization of healthcare resources, resulting in lower overall healthcare costs. [22] [23] [24] Despite this fact, preventive migraine treatments are underutilized in clinical practice. 25, 26 Similarly, as demonstrated for direct costs, preventive migraine treatment has been shown to reduce migraine-related productivity losses. 18, 23 Given the frequently disabling nature of migraine and its high prevalence, especially during peak productive years, and the lack of recent estimates of the burden of migraine, there is a need to update the existing literature with more recent data, to quantify both direct and indirect costs in patients with migraine, and to provide employers, health plans, healthcare providers, and policy makers with an up-to-date understanding of the costs associated with migraine. Therefore, the goal of this retrospective analysis was to build on these prior studies and provide a contemporary estimate of the burden of migraine, incorporating both direct and indirect costs, by comparing the costs of migraine patients to a matched group of patients without migraine in a large, nationally representative sample of commercially insured patients in the United States. Approximately 70 large employers contribute data to the HPM database. The HPM data are linkable to the corresponding medical and pharmacy claims data for these employees. All study data were accessed with protocols compliant with United States patient confidentiality requirements, including the Health Insurance Portability and Accountability Act (HIPAA) of 1996 regulations. As the MarketScan databases used in this study have undergone analysis by a third party to verify that the HIPAA requirements for fully deidentified data sets have been met, this study was exempted from institutional review board approval.
Study Population.-Two cohorts of patients were selected for this study, one with migraine and a second without migraine. Patients were selected into the migraine cohort if they met at least one of the following criteria indicating evidence of migraine (2) had at least two outpatient (OP) claims (7-180 days apart) with a migraine diagnosis in any diagnosis position; (3) had at least one OP claim with a migraine diagnosis in any diagnosis position and at least one OP pharmacy claim for a triptan, ergot, or topiramate (7-180 days apart); (4) had at least two OP pharmacy claims for a triptan or ergot (7-180 days apart). The date of first diagnosis or treatment was defined as the index date.
Patients with no medical claims with a diagnosis of migraine and no OP pharmacy claims for a triptan, ergot, or topiramate between January 1, 2007 and June 30, 2014 were initially selected for inclusion in the no migraine (control) cohort. Index dates for the no migraine controls were set to match those of their matched counterparts in the migraine cohort (please see below for a description of the matching).
In addition to meeting the above criteria for inclusion in either the migraine or no migraine cohort, patients were required to have continuous health plan coverage for at least 12 months before (baseline period) and after (follow-up period) the index date and to be adults (age 18 years) on the index date. Patients with a diagnosis of HIV (ICD-9-CM diagnosis 042.xx-044.99) or with any malignant neoplasm (except of skin; ICD-9-CM diagnosis 140.xx-172.99; 174.xx-195.99; 200.xx-208.99) at any point during the baseline or follow-up periods or with a diagnosis or procedure code indicative of pregnancy or childbirth during the follow-up period were excluded from the study. Finally, patients in the migraine and nonmigraine cohorts were required to have at least 12 months of enrollment in WA, ST disability, or LT disability benefits following the index date. Because employers may contribute one, two, or all three HPM data types to the HPM database, an individual patient in the migraine or no migraine cohort could contribute data to one, two, or all three of the HPM cohorts. The work absence days captured in each of the three HPM databases are nonoverlapping (eg, a ST disability period would end prior to the commencement of a LT disability period), which prevents double counting of costs. The patient selection process is presented in Figure 1 .
Direct Matching.-As this is an observational study and randomization of patients was not possible, patients in the control cohort were directmatched to those selected for the migraine cohort on basic demographic characteristics at a 1:1 ratio. Matching factors included age in years, gender, region, and health plan type. For all variables, matches were required to be exact (ie, based on identical values); if more than one nonmigraine match was available for a migraine patient, the patient was selected randomly from the available options. Index dates for the individuals in the control cohort were set to those of their matched counterparts in the migraine cohort. Separate direct matches were conducted for the WA, ST disability, and LT disability analyses. Matching was performed using SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA).
Study Covariates.-The demographic variables measured as of the index date and the clinical variables evaluated during the 12-month baseline period are listed in Tables 1 and 2 .
Outcome Measures.-Direct, all-cause healthcare utilization and costs were evaluated during the 12-month follow-up period. Direct healthcare utilization and costs were assessed overall and for healthcare services in the IP, ER, OP (physician office visits, brain imaging procedures, other outpatient services), and OP pharmacy settings. Migrainerelated outpatient pharmacy utilization and costs were also evaluated during the follow-up period. Patients with pharmacy claims for preventive migraine medications (select anticonvulsants, select antidepressants, select beta blockers, and onabotulinumtoxinA) and prescription acute migraine medications (triptans, ergots, opioids, and nonsteroidal anti-inflammatory drugs [NSAIDs]) were flagged and the total costs on these claims were recorded. Direct healthcare costs were expressed in 2014 constant dollars, adjusted using the Medical Care component of the Consumer Price Index and were measured using the financial fields on administrative claims in the Commercial database. Direct healthcare costs included the gross covered payments for all healthcare services or products, which includes both payer-paid costs and patient-paid outof-pocket costs, ie, the amount eligible for payment after applying pricing guidelines such as fee schedules and discounts, but including deductibles, copayments, and coordination of benefits.
For the analysis of indirect costs, the number and percentage of patients with a claim for each benefit type, the days lost due to each benefit type, and the indirect costs associated with that benefit type were measured during the 12-month follow-up period. WA, ST disability, and LT disability days were extracted directly from claims in the HPM database. The reason for work absence, ST, or LT disability is not recorded on the claim; therefore, these can be absences for any cause. Indirect costs were calculated by multiplying the number of days absent during the follow-up period with an average hourly wage of $41/hour. 27, 28 This estimate is based on United States Bureau of Labor Statistics (BLS) for large companies, similar to those in the HPM database and then adjusted using the Social Security Administration National Wage Index. 29, 30 As ST/LT disability benefits typically do not provide full wage replacement, a rate of 70%, which approximates the proportion of total wages paid by employers in the HPM database, was applied to the BLS wage rate when calculating the indirect costs of ST and LT disability. 29 Total indirect costs, calculated as cost of WA plus cost of ST disability plus cost of LT disability, were also computed. Statistical Analysis.-To test for statistically significant differences between the migraine and nonmigraine cohorts, chi-square tests were conducted on categorical measures and t-tests on continuous measures. Separate analyses were conducted in the subsets of patients with WA, ST disability, and LT disability data eligibility. Two multivariable logistic regression analyses were conducted. First, an analysis was conducted comparing the odds of having an ST disability claim during the follow-up period between patients with and without migraine after controlling for the patient demographic characteristics and clinical characteristics measured during the 12-month baseline period listed in Tables 1 and 2 . A second analysis, conducted among the migraine patients only, compared the odds of having an ST disability claim during the follow-up period between (1) patients treated with acute or preventive migraine medications only during the baseline period and patients with no migraine treatment during baseline and (2) between patients treated with both acute and preventive migraine medications during the baseline period and patients with no migraine treatment during baseline, after controlling for patient demographic and clinical characteristics. For this analysis, the acute medications considered were triptans, ergots, opioids, and prescription NSAIDs and the Variable was used in the propensity score match; standardized differences were zero for all variables. preventive migraine medications considered were topiramate, valproic acid, amitriptyline, propranolol, timolol, and onabotulinumtoxinA. Several matching variables were included in the multivariate models as they may have also predicted ST disability, independent of migraine status. Data extraction was performed using SAS Version 9.2 (SAS Institute Inc.). For all statistical analyses, P values < .01 were considered, a priori, to be statistically significant; use of a more stringent threshold for statistical significance than the commonly used threshold of P < .05 was due to the multiple comparisons presented in this analysis.
RESULTS
Study Population.-After applying the study inclusion and exclusion criteria and conducting the matching, the final samples consisted of 12,642 pairs of matched patients with WA eligibility, 71,742 pairs with ST disability eligibility, and 66,587 pairs with LT disability eligibility (Fig. 1) . The matching rate was high, with only 1.2% of migraine patients lost in the WA match, 0.5% lost in the ST disability match, and 0.4% lost in the LT disability match.
Patient Characteristics.-Since there was a large degree of overlap in the samples included in the matched WA, ST disability, and LT disability cohorts, the characteristics of the three samples were similar. As the ST disability cohort was the largest of the three (n 5 71,742 matched pairs), data for this group are displayed in Tables 1 and 2 ; characteristics of the WA and LT disability cohorts are available in Supporting Information Tables 1 and 2 . After matching, patients with and without migraine had similar demographic characteristics ( Table 1) . The mean age of the migraine and no migraine cohorts was 41.4 years (standard deviation [SD] 5 9.7 years). Patients were predominantly (Table 2) . Annual All-Cause Direct Healthcare Utilization and Costs.-As above, direct healthcare utilization and cost results for the ST disability cohort are presented here (Table 3) ; direct costs in the WA and LT disability cohorts were similar and are available in Supporting Information Table 3 . In the ST disability cohort, migraine patients' mean annual direct all-cause healthcare costs were $6575 higher than those of matched patients without migraine ($11,010 [SD 5 $19,663] vs $4436 [SD 5 $13,081]; P < .01). Direct costs were significantly higher in the migraine cohort as compared to the no migraine cohort in each of the individual service categories (IP, ER, OP, and OP pharmacy; all P < .01; Table 3 ). Of the $6575 in incremental healthcare costs, 47% was for OP services ($3075), 26% was for OP medications ($1730), 20% was for IP services ($1334), and the remaining 7% ($436) was for ER services.
Migraine patients were 3.0 times more likely to have an IP admission (8.6% vs 2.9%; P < .01) and 2.4 times more likely to have an ER visit (33.8% vs 14.3%) as compared to matched patients without migraine. Compared to patients without migraine, those with migraine were more likely to have a physician office visit during the 12-month follow-up period (97.2% vs 82.6%) and had a significantly higher mean number of physician office visits per year (7. Preventive and prescription acute migraine medication utilization and costs in the ST disability cohort are reported in Table 4 (see Supporting  Information Table 4 for the WA and LT disability cohorts). The incremental cost of migraine-related medications was $840, with the majority (83.2%) of this incremental cost arising from the cost of prescription acute migraine medications. Patients in the migraine cohort were significantly more likely than those in the no migraine cohort to use antidepressants (7.1% vs 0.5%; P < .01). Migraine patients were also more than twice as likely as their nonmigraine counterparts to use opioids (45.5% vs 21.9%; P < .01) and among patients with opioid prescriptions, migraine patients had a significantly higher number of opioid prescriptions per patient than did those without migraine (4.9 [SD 5 6.9] vs 2.7 [SD 5 4.0]; P < .01). Use of prescription NSAIDs was also more common in the migraine cohort as compared to the no migraine cohort (31.9% vs 17.1%; P < .01), although the cohorts did not differ in the number of NSAID prescriptions per patient.
Annual Indirect Costs.-Work days lost due to WA, ST disability, and LT disability and the associated indirect costs are displayed in Table 5 . Total (WA 1 ST disability 1 LT disability) mean annual indirect costs were $2350 higher in the migraine cohort than in the matched no migraine patients ($11,294 vs $8945). Migraine patients had significantly ($1043) higher WA costs than controls ($9304 vs $8261; P < .01), which was driven by more WA days during follow-up (28.4 days [SD 5 22.7) vs 25.2 days [SD 5 19.3]; P < .01).
Migraine patients were 2.5 times as likely to have a ST disability claim (16.7% vs 6.7%; P < .01) and lost 3.1 times as many work days to ST disability (8.0 days vs 2.6 days; P < .01) as compared to their matched counterparts without migraine. The higher number of ST disability days in the migraine cohort as compared to the no migraine cohort was associated with $1224 in incremental indirect costs ($1828 [SD 5 $6098] vs $603 [SD 5 $3278]); P < .01).
After adjusting for the demographic and clinical characteristics measured during the 12-month baseline period, migraine patients (treated and untreated) had 1.94 times the odds of having an ST disability claim than their matched counterparts without migraine (95% confidence interval [CI] 5 1.83-2.05; P < .01). (See Supporting Information Tables 5 and 6 .98]; P < .01) were significantly less likely to have ST disability claims than untreated patients during the follow-up period. While there may be some benefit on disability with current migraine therapy, there is significant room for improvement since patients with prophylactic and/or acute medications were associated with high indirect costs ranging from $10,889 to $11,539.
While LT disability was rare in both cohorts, migraine patients were 2. 
DISCUSSSION
In this assessment of the cost burden of migraine in a large sample of used, commercially insured adults in the United States, we found that migraine patients have total annual direct plus indirect costs that are $8924 (in 2014 USD) higher than those of demographically similar individuals without evidence of migraine. Direct healthcare costs accounted for 74% of the total incremental cost of migraine; of the $6575 per patient in incremental direct costs, 47% was for OP services ($3075), 26% was for OP medications ($1730), 20% was for IP services ($1334), and the remaining 7% ($436) was for ER services. Indirect costs were $2350 higher annually in migraine patients than in those without migraine, a result of 8.9 more missed days of work each year among individuals with vs without migraine.
Some of the most recent published estimates of the direct and indirect costs of migraine in the United States based on administrative claims data and using similar methods to ours were produced in two studies conducted by Hawkins and colleagues using data that are now a decade old. 10, 19 In a study of direct costs only, the annual all-cause healthcare costs of patients with migraine were compared to those of a matched sample of individuals without migraine. 10 . The Hawkins analysis also ignored indirect costs, which account for one-fourth (26.3%) of the burden of migraine. In a second study, in addition to direct healthcare costs, the costs of WA, ST disability, and workers' compensation were compared between matched cohorts of employed adults with and without migraine. 19 As in this study, indirect costs were estimated by multiplying actual days reported lost due to WA, ST disability, or workers' compensation by an average wage rate, with a 70% adjustment to account for typical wage replacement rates for the latter two types of work loss. The annual incremental indirect cost of migraine across the three work loss types was estimated at $2834 (in 2004 USD, adjusted to $3548 in 2014 USD) and the annual incremental direct cost of migraine at $1737 ($2438 in 2014 USD), for a total annual incremental cost of migraine estimated at $4571 ($5986 in 2014 USD); in this latter study, direct healthcare costs accounted for 62% of the total incremental cost of migraine. Even after converting Hawkins and colleagues' results to 2014 USD equivalents, our present estimate of the annual incremental all-cause direct cost of migraine was over 2.5 times higher than that of the Hawkins et al 19 estimate ($6574 vs $2438) based on healthcare utilization patterns from over a decade ago. Neither of the Hawkins studies presented all-cause direct costs by healthcare service category, preventing the identification of the components of cost that are the major contributors to this increase over the previous decade. However, it appears that the direct costs associated with the treatment of migraine in the United States have increased substantially. Most of the more contemporary estimates of the burden of migraine in the United States have come from studies using survey data. 7, 15, 16, 21, 32, 33 One of the most recent cost estimates comes from the International Burden of Migraine Study. 1, 7 Participants were adults willing to participate in webbased health surveys identified as having episodic migraine (EM) or chronic migraine (CM) based on self-reported headache symptoms and frequency. Individuals with EM and CM were asked to report headache-related healthcare utilization within the most recent 3 months and medication use within the most recent month. Self-reported resource use was converted to direct costs (in 2013 USD) using cost estimates for individual services and medications. Productivity losses were assessed via selfreported number of work/school days missed or with productivity reduced by more than 50% during the previous three months and were transformed into indirect costs by multiplying by an average hourly wage rate of $22.65. The annual total (direct 1 indirect) migraine-related cost estimates derived from this study were $8243 for CM (n 5 104) and $2649 for EM (n 5 1101). To compare these results to the present results, which did not stratify by migraine severity, we computed the weighted average across CM and EM patients in the Messali et al 7 study. Annual, migraine-related total costs across all migraine patients were calculated to be $3132 (2013 USD), which is substantially lower than our estimate of $8924 (in 2014 USD) in incremental costs. A similar survey study conducted by Munakata and colleagues using slightly older data 15 also provided much lower estimates of the cost burden of migraine as compared to those presented in this study. One possible explanation for the lower cost estimates provided by the survey studies as compared to ours is that the survey studies requested that participants report healthcare utilization and lost productivity specifically due to headache, whereas we computed the costs of all-cause healthcare utilization and all-cause work absences in patients with vs without migraine. Therefore, the direct and indirect costs reported in the survey studies are migraine-specific costs, but the costs reported in this study include those specific to migraine as well as those related to comorbid conditions. We observed a significantly higher comorbid burden in the migraine patients as compared to those without migraine (Table 2) . For example, the rates of anxiety (7.9% vs 3.2%) and depression (11.2% vs 4.3%) were significantly higher in individuals with vs without migraine. Previous studies have found higher healthcare costs among migraineurs with comorbid anxiety and/or depression than those without. 12, 13 Many of the comorbidities that were more prevalent in the migraine sample have also been found to be associated with increased indirect costs; for example, depression and anxiety, 34, 35 osteoarthritis, 36 and inflammatory bowel disease. 37 Another explanation for the lower costs reported in the survey study is that the average hourly wage rate used in that study was lower than that used in this study. The higher rate used in the current study was appropriate for a commercially insured population. Finally, estimated costs may have been lower in the survey studies as compared to the claims-based studies because the former relied on patient recall of their healthcare utilization, which may have been incomplete, whereas the latter relied on a record of actual healthcare utilization. The design of the survey studies described above does have some advantages over that of this study: the patient samples are not limited to used individuals or to individuals with health insurance, they account for lost productivity outside of the workplace, and they account for lost productivity due to presenteeism. However, survey studies also have weaknesses compared to claims-based studies. They rely on self-reports of healthcare resource utilization, medication use, and reduced productivity during a limited (usually 3 months) time frame rather than on administrative records of healthcare utilization and missed work days over a longer time period. Additionally, direct costs in those survey studies that have attempted to monetize selfreported utilization are calculated based on estimates of unit costs for various services, procedures, and medications rather than based on actual paid amounts on medical and pharmacy claims.
Several additional limitations of this study should be noted. The diagnosis of migraine and clinical characteristics were determined using ICD-9-CM diagnosis or procedure codes, which are subject to data coding limitations and data entry error. Migraine occurrence or related symptoms which were not recorded as a diagnosis on a medical claim, use of over-thecounter medications, and other self-management techniques are not captured in claims data. Additionally, ICD-9-CM coding for migraine lacks the specificity necessary to determine migraine severity. As a result, this analysis is limited in its ability to fully account for the full burden of migraine. Pharmacy claims do not contain a diagnosis code; therefore, it is not known whether the acute and preventive migraine medications considered in this study, all of which may also be prescribed for other indications, were used to treat migraine, even in the migraine cohort. One consequence of this limitation is that patients who were selected into the migraine cohort based on the presence of two pharmacy claims for a triptan or ergot may have been using these medications to treat cluster headache rather than migraine. Because WA, ST, and LT disability claims do not include the reason for the absence, we have not isolated the costs of work loss specifically resulting from the occurrence of migraine; however, by comparing the costs of work loss in patients with migraine to those in a matched group of patients without migraine, we have isolated the costs of work loss related to migraine and any other conditions that tend to co-occur with migraine. Finally, because research databases used for the present study contain data for individuals with employer-sponsored health insurance, the present findings may not be generalizable to individuals with other types of insurance (eg, Medicaid) or the uninsured.
CONCLUSIONS
Results from this real-world assessment of the economic burden of migraine suggest a substantial direct and indirect cost burden compared to demographically similar nonmigraine patients. Compared to matched nonmigraine patients, migraine patients were more likely to have work loss and longer periods of work loss, leading to significantly higher indirect costs. Migraine patients also had higher levels of utilization for every type of healthcare resource utilization, despite the relatively stable prevalence of migraine and the available acute and preventive treatment options for migraine management. In fact, we found an increase in the direct and indirect costs of migraine compared to similar studies conducted a decade ago, which highlights the lack of availability of optimal therapeutic options. Future research should continue to explore the burden of migraine, as well as the underlying causes of the increasing cost burden to provide context for the rapidly changing migraine treatment landscape. Future research should additionally focus on identifying more severe migraine patients and their potential impact on the overall burden of migraine. In one example of such a study, in an analysis of the same dataset presented here, a strong association between high triptan and opioid use and being in the top quartile of direct, all-cause healthcare costs was demonstrated. 38 Finally, research on the impact of treatment adherence on healthcare utilization and costs would be beneficial. 
